

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1624

Carlos GARCIA-ECHEVERRIA et al.

Examiner: RAO, Deepak R.

APPLICATION NO: 10/568,367

FILED: 18 August 2006

FOR: 2,4-Pyrimidinediamines Useful in the Treatment of Neoplastic
Diseases, Inflammatory and Immune System Disorders

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES**

Sir:

The Notice to Comply with Requirements mailed 30 January 2009 has a shortened statutory time set to expire on 30 July 2009, with the enclosed three-month extension of time fee.

In response, applicant now submits a separate paper copy of the Nucleotide and/or Amino Acid Sequence Submission, the corresponding Computer Readable Form (CRF), and a statement verifying identity of above copies. Please amend the application to introduce the Sequence Listing therein.

The Commissioner is hereby authorized to charge the three-month extension of time fee and any additional fees under 37 CFR §1.17 which may be required to Deposit Account No. 50-4409 in the name of Novartis.

Respectfully submitted,

Novartis Institutes for BioMedical Research, Inc.
220 Massachusetts Avenue
Cambridge, MA 02139

(617) 871-7347

Date: 30 July 2009



Mark E. Baron
Attorney for Applicant
Reg. No. 46,150